WHO ICTRP trial
Clinical study investigating the safety PG545 in combination with nivolumab in…
ACTRN12617001573347 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Not Recruiting
Key facts
| Trial ID | ACTRN12617001573347 |
|---|---|
| Public title | Clinical study investigating the safety PG545 in combination with nivolumab in patients with advanced solid tumours and in patients with metastatic pancreatic cancer |
| Scientific title | An open-label, multi-centre Phase Ib study of the safety and tolerability of IV infused PG545 in combination with nivolumab in patients with advanced solid tumours with an expansion cohort in patients with metastatic pancreatic cancer |
| Primary sponsor | Scientia Clinical Research Limited |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 1 |
| Countries | Australia |
| Conditions | Advanced solid tumours;Pancreatic Cancer;Colorectal cancer; Advanced solid tumours Pancreatic Cancer Colorectal cancer;Cancer - Pancreatic;Cancer - Bowel - Back passage (rectum) or large bowel (colon) |
| Interventions | Stage 1: Dose escalation in patients with advanced or metastatic solid tumours: PG545 25, 50 or 100 mg once weekly via IV infusion and Nivolumab 240 mg every two weeks via IV infusion. Patients receive weekly doses of PG545 according to the… |
| Registration date | Nov 22, 2017 |
| Target size | 62 |
| Secondary IDs | ZU545102;CA209-9KJ |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: